Pharmafile Logo
Pharmafocus logo
Advanced Search

Genentech

Showing 15 posts of 87 posts found.

lungs

Genentech shares phase 3 results for ALK-positive early-stage lung cancer treatment

September 1, 2023
Research and Development Genentech, NSCLC, Oncology, clinical trials, lung cancer

Roche’s Genentech has announced that the phase 3 ALINA trial assessing Alecensa, compared with platinum-based chemotherapy for the treatment of …

News
needle-1291170_960_720

Genentech shares results from phase 3 trial for MS treatment

July 13, 2023
Research and Development Genentech, MS, Neurology, Ocrevus, clinical trial

Genentech has announced positive results from its phase 3 OCARINA II trial which assessed Ocrevus (ocrelizumab) as a twice-a-year, ten-minute …

News

Genentech’s injectable eye medicine extends time between treatments for two conditions

February 15, 2021
Sales and Marketing Genentech

Genentech has announced detailed, positive results from four Phase III studies of its investigational bispecific antibody, faricimab, for the treatment …

News
genentech_web

Genentech announces positive top-line results for “wet” age-related macular degeneration antibody

January 25, 2021
Sales and Marketing Genentech

Genentech has announced positive top-line results from two identically designed global Phase III studies, TENAYA and LUCERNE, evaluating its investigational …

News
160607140346-genentech-lung-cancer-drug-settlement-exlarge-169

Genentech’s cancer drug gets Breakthrough Therapy Designation from FDA

January 5, 2021
Manufacturing and Production Cancer, Genentech

Genentech has announced that tiragolumab, a novel cancer immunotherapy designed to bind to T cell immunoreceptor with Ig and ITIM …

News
genentech_web

Genetech scores sixth FDA approval in lung cancer with Gavreto

September 7, 2020
Sales and Marketing Cancer, FDA, Genentech, lung cancer

Genentech’s once-daily oral therapy Gavreto (pralsetinib) has secured FDA backing in the treatment of metastatic rearranged during transfection (RET) fusion-positive …

News
fdaoutsideweb

Genentech’s Evrysdi becomes first FDA-approved oral treatment for spinal muscular atrophy

August 10, 2020
Sales and Marketing Evrysdi, FDA, Genentech, Roche, spinal muscular atrophy

Genentech’s Evrysdi (risdiplam) has secured FDA approval for the treatment of spinal muscular atrophy (SMA), making it the first oral therapy …

News
shutter

UCB syncs up with Roche and Genentech in Alzheimer’s drug deal worth a potential $2bn+

July 30, 2020
Research and Development, Sales and Marketing Genentech, Roche, UCB, partnership

UCB Pharma is set to partner up with Roche and Genentech in a development and commercialisation deal focused on its …

News
tecentriq

Roche’s Tecentriq fails to hit main Phase 3 goal in front-line ovarian cancer

July 13, 2020
Research and Development, Sales and Marketing Genentech, Roche, ovarian cancer, tecentriq

Roche subsidiary Genentech has revealed that its immunotherapy Tecentriq (atezolizumab), combined with Avastin (bevacizumab), paclitaxel and carboplatin, fell short of …

News

Roche’s Tecentriq improves pathological complete response in triple-negative breast cancer at Phase 3

June 19, 2020
Medical Communications, Research and Development Cancer, Genentech, Roche, breast cancer, tecentriq

 

News
aviv_regev

Genentech’s retiring R&D head to be replaced by MIT executive

May 15, 2020
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Genentech, Roche, appointment

Michael Varney, industry veteran and Head of Research & Development at Genentech, has announced he is to leave the role …

Appointment
roche

Roche signs deal with Skyhawk over molecules that modulate RNA splicing

July 17, 2019
Research and Development Genentech, Roche, Skyhawk, drug development, rna splicing

Roche’s Genentech unit has signed a deal with Massachusetts-based firm Skyhawk Therapeutics to develop and commercialise small molecules that modulate …

News
genentech_web

Genentech signs $1 billion deal with Sosei over GCPRs

July 17, 2019
Research and Development Genentech, Roche, gcprs, pharma, sosei

Roche’s Genentech has entered into a partnership with Sosei Heptares to develop small molecules and biologics that G protein-coupled receptor …

News

FDA greenlights Pfizer biosimilar version of Genentech’s Avastin

July 1, 2019
Sales and Marketing Cancer, Genentech, Pfizer, pharma, pncology

Pfizer is celebrating the approval by the FDA of Zirabev, its biosimilar version of Genentech’s Avastin (bevacizumab), which is now …

News
genentech_web

Ocrevus becomes first NICE-approved therapy on the NHS for primary progressive multiple sclerosis

May 9, 2019
Sales and Marketing Genentech, NHS, NICE, Ocrevus, UK

NICE has announced its final appraisal decision on Genentech’s Ocrevus (ocrelizumab), choosing to recommend the drug for use on the …

News

Latest content

Novo Nordisk partners with UNICEF to prevent global childhood obesity

September 21, 2023

EC approves Menarini Group’s Orserdu for breast cancer treatment

September 21, 2023

Pharmanovia acquires CNS portfolio from Sanofi

September 20, 2023

Exscientia enters AI drug discovery collaboration with Merck KGaA

September 20, 2023

EC approves Pfizer’s Litfulo for adolescents and adults with alopecia

September 19, 2023